Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 9/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL99075 | 1.00 | CHRM3 (0.50) | CHRM3CHRM1CHRM2ADRB2CHRM4 | |
| SCHEMBL98861 | 0.93 | CHRM3 (0.50) | CHRM3CHRM1CHRM2ADRB2CHRM4 | |
| SCHEMBL100281 | 0.91 | CHRM3 (0.54) | CHRM3CHRM1CHRM2CHRM4TSHR | |
| SCHEMBL100663 | 0.91 | CHRM3 (0.55) | CHRM3CHRM1CHRM2ADRB2CHRM4 | |
| SCHEMBL100662 | 0.91 | CHRM3 (0.55) | CHRM3CHRM1CHRM2ADRB2CHRM4 | |
| SCHEMBL99947 | 0.88 | CHRM3 (0.45) | CHRM3CHRM1CHRM2ADRB2CHRM4 | |
| SCHEMBL98251 | 0.87 | CHRM3 (0.56) | CHRM3CHRM1CHRM2CHRM4TSHR | |
| SCHEMBL98250 | 0.87 | CHRM3 (0.56) | CHRM3CHRM1CHRM2CHRM4TSHR | |
| SCHEMBL100649 | 0.86 | CHRM3 (0.46) | CHRM3CHRM1CHRM2ADRB2CHRM4 | |
| SCHEMBL661597 | 0.86 | CHRM3 (0.46) | CHRM3CHRM1CHRM2ADRB2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | TEIJIN PHARMA LIMITED (JP) | 2012-02-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | ADRB2, AGTR2, ADRB3 | CHRM3 9/4885CHRM1 25/4885CHRM2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.